文献速递类风湿关节炎

巴瑞替尼改善类风湿关节炎患者的骨性质与生物力学:前瞻性干预性BARE BONE试验结果

Baricitinib Improves Bone Properties and Biomechanics in Patients With Rheumatoid Arthritis: Results of the Prospective Interventional BARE BONE Trial.
PubMed 文献 · Arthritis Rheumatol · 2023-09-21

BARE BONE试验为前瞻性、单臂、干预性、开放标签、单中心4期研究,纳入30例有骨病理状态且临床有JAK抑制剂指征的类风湿关节炎患者,接受巴瑞替尼4 mg/日治疗52周。结果显示疾病活动度与滑膜炎显著改善,小梁骨容积骨密度及生物力学性质显著改善,掌骨关节侵蚀数目和大小保持稳定,未观察到新的安全信号。

要点

  • 巴瑞替尼4 mg/日治疗52周可显著改善类风湿关节炎疾病活动度与滑膜炎。
  • 小梁骨容积骨密度平均变化为6.11 mgHA/mm3(95%CI 0.01-12.26)。
  • 估计刚度与估计失效载荷平均变化分别为2.28 kN/mm与98.8 N,掌骨侵蚀保持稳定。

核心结论

  • 巴瑞替尼治疗可改善类风湿关节炎患者的骨性质,表现为小梁骨量增加和生物力学性质改善。

研究设计与样本

  • 前瞻性、单臂、干预性、开放标签、单中心4期研究(BARE BONE试验),纳入30例有骨病理状态且临床有JAK抑制剂指征的类风湿关节炎患者,接受巴瑞替尼4 mg/日治疗52周。

主要发现

  • 疾病活动度(基于红细胞沉降率的28关节疾病活动度评分)从4.82±0.90降至2.71±0.83,滑膜炎RAMRIS评分从5.3(4.2)降至2.7(3.5)。
  • 小梁骨容积骨密度平均变化为6.11 mgHA/mm3(95%CI 0.01-12.26)。
  • 估计刚度平均变化为2.28 kN/mm(95%CI 0.30-4.25),估计失效载荷平均变化为98.8 N(95%CI 15.9-181.7)。
  • 掌骨关节侵蚀的数目和大小保持稳定,未观察到巴瑞替尼治疗的新安全信号。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Rheumatoid arthritis (RA) is characterized by erosive joint damage, deterioration of bone mass, and biomechanics. Preclinical evidence suggests a beneficial effect of Janus kinase inhibition (JAKi) on bone properties, but clinical data are scarce to date. In this study, we evaluated the effect of JAKi through baricitinib (BARI) on 1) volumetric bone mineral density (vBMD), bone microstructure, biomechanics, and erosion repair and 2) synovial inflammation in RA patients. METHODS: Prospective, single-arm, interventional, open-label, single-center phase 4 study in RA patients with pathological bone status and clinical indication of JAKi (BARE BONE trial). Participants received BARI (4 mg/day) over 52 weeks. To assess bone properties and synovial inflammation, high-resolution computed tomography scans and magnetic resonance imaging were performed at baseline (BL), week 24, and week 52. Clinical response and safety were monitored. RESULTS: Thirty RA patients were included. BARI significantly improved disease activity (Disease Activity Score in 28 joints using the erythrocyte sedimentation rate: 4.82 ± 0.90 to 2.71 ± 0.83) and synovial inflammation (RAMRIS synovitis score: 5.3 [4.2] to 2.7 [3.5]). We observed a significant improvement in trabecular vBMD with a mean change of 6.11 mgHA/mm3 (95% confidence interval [95% CI] 0.01-12.26). Biomechanical properties also improved with mean change from baseline in estimated stiffness of 2.28 kN/mm (95% CI 0.30-4.25) and estimated failure load of 98.8 N (95% CI 15.9-181.7). The number and size of erosions in the metacarpal joints remained stable. No new safety signals with BARI treatment were observed. CONCLUSION: Bones of RA patients improve with BARI therapy, as shown by an increase in trabecular bone mass and an improvement of biomechanical properties.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Simon D, Minopoulou I, Kemenes S, et al. Baricitinib Improves Bone Properties and Biomechanics in Patients With Rheumatoid Arthritis: Results of the Prospective Interventional BARE BONE Trial. Arthritis Rheumatol. 2023. PMID: 37229650. doi:10.1002/art.42617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。